The study also linked the use of Zofran in early pregnancy with a doubled risk of cardiac septal defects, including atrial septal defect and ventricular septal defect
Conclusions: First trimester ondansetron use is associated with an increased risk of neonatal VSD potentially driven by higher doses
11
2% of all newborns
Ventricular Septal Defects (VSD) Nearly 1% of babies are born with a heart defect, and Ventricular Septal Defect (VSD) is one of the most common birth defects
Ondansetron Generic name: ondansetron (oral) [ on-DAN-se-tron ] Brand names: Zofran, Zofran ODT, Zuplenz Drug class: 5HT3 receptor antagonists Medically
Key foci include the chemoreceptor trigger zone in the floor of the fourth ventricle and the vomiting centre in the medulla with inputs from the nucleus tractus
Ondansetron is one of the medications most commonly used for the empiric treatment of nausea and vomiting
A small ventricular septal defect (VSD) may never cause any problems
Other side effects of Zofran include dizziness and nervousness
Zofran is in the drug class 5HT3 receptor antagonists
Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect
Zofran, with its targeted action on specific receptors in the body, has emerged as a ray of hope for patients suffering from these debilitating symptoms
Bottom Line
Zofran, an anti-nausea drug commonly prescribed “off-label” to pregnant women with morning sickness, has been linked to an increased risk of heart defects, Ventricular Septal Defect (VSD): This is a hole between the two lower chambers (ventricles) of the heart
The nausea and morning sickness drug Zofran has been linked to an increased risk of birth defects when used by women during pregnancy
Compare Zofran vs
sitelike
The dangers of Zofran for use within a pregnancy are especially remarkable Apparently Zofran has been shown to double the risk of heart defects as well as mouth deformities when taken during the first trimester, which is when these were prescribed
2015: More than 200 adverse event reports have been submitted involving Zofran birth defects between 1992 and early